Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer September 9, 2021
Touting CD161 as a Test Case for Single-Cell Tech, Longwood-backed Immunitas Bags $58M for Next-Gen I/O Work August 19, 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases August 18, 2021
Immunitas Therapeutics and Lonza Announce Manufacturing Agreement to Rapidly Advance Lead Program to the Clinic April 16, 2021
Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology February 18, 2021
